<DOC>
	<DOCNO>NCT00004233</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Chemoprotective drug triacetyluridine may protect normal cell side effect chemotherapy . PURPOSE : Phase II trial study effectiveness triacetyluridine , fluorouracil , leucovorin treat patient unresectable , locally advanced , metastatic cancer esophagus stomach .</brief_summary>
	<brief_title>S9915 Triacetyluridine , Fluorouracil , Leucovorin Treating Patients With Unresectable , Locally Advanced , Metastatic Cancer Esophagus Stomach</brief_title>
	<detailed_description>OBJECTIVES : - Assess 6-month survival rate patient unresectable , locally advanced metastatic adenocarcinoma stomach gastroesophageal junction treat triacetyluridine , fluorouracil , leucovorin calcium . - Evaluate qualitative quantitative toxic effect regimen patient . OUTLINE : This multicenter study . Patients receive leucovorin calcium IV 2 hour fluorouracil IV 30 minute begin 1 hour leucovorin calcium infusion day 1 , 8 , 15 , 22 , 29 , 36 . Patients receive oral triacetyluridine every 8 hour day 1-3 , 8-10 , 15-17 , 22-24 , 29-31 , 36-38 begin 8 hour completion fluorouracil infusion . Courses repeat every 8 week absence disease progression unacceptable toxicity . Patients follow every 6 month 3 year . PROJECTED ACCRUAL : A total 53 patient accrue study .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven unresectable , locally advanced metastatic adenocarcinoma stomach gastroesophageal junction No known brain metastasis Negative brain imaging require neurologic sign symptom PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin great upper limit normal ( ULN ) SGOT SGPT great 1.5 time ULN ( 5 time ULN liver tumor present ) Renal : Creatinine great ULN Other : Not pregnant nursing Fertile patient must use effective contraception Must able swallow oral medication No AIDS syndrome HIVassociated complex No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer complete remission PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy No concurrent biologic therapy Chemotherapy : No prior chemotherapy advance metastatic gastric cancer At least 6 month since prior chemotherapy adjuvant radiation sensitizer Endocrine therapy : Not specify Radiotherapy : At least 1 month since prior radiotherapy recover No concurrent radiotherapy Surgery : At least 3 week since prior major surgical resection intraabdominal organ recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>